|
 |
 Home > Available Issues |
|
|
 Original Articles |
| Clinical Efficacy and Safety of Cefodizime compared to Ceftriaxone in the Treatment of Community-Acquired Pneumonia |
| Hyung Seok Choi, Hee Soon Jeong, Myoung Don Oh, Chul Gyu Yoo, Young Whan Kim, Sung Koo Han, Kang Won Choe, Young-Soo Shim |
| Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea |
Vol.26 Num.3 (p271~277)
|
|
|
Background: Cefodizime((R)Modivid) is a new parenteral form of cephalosporin showing the antibacterial specturm of the third generation. The clinical efficacy and safety of cefodizime have been well proven by some previous clinical studies performed in European countries and Japan. The objective of this study was to evaluate the clinical, radiological and antimicrobial efficacy of this drug in patients with community-acquired pneumonia compared to that of ceftriaxone.
Methods: We performed an open, controlled, randomized study in 32 patients with community-acquired pneumonia at Seoul National University hospital from June 1992 to November 1993. In the first group(n = 11) 1g of cefodizime, and in the second group (n = 10) 2g of cefodizime were respectively administered intravenously once a day. And in the third group(n = 11), 1g of ceftriaxone was administered intravenously.
Results: The results were as follows.
1) Cefodizime showed the clinical response rate of 100% in group I, and 80.0% in groupII. The clinical response rate of ceftriaxone in group III was 81.8%. There was no significant statistical difference (p>0.05).
2) The rates of bacteriological efficacy were not statistically different among three groups.
3) In the cefodizime treatment group(group I, group II) nausea and vomiting were observed in 2 cases(9.5%) and transient elevations of hepatic transaminases in 1 case(4.8%). Mild abdominal pain occurred in 1 case(4.8%). No significant adverse reactions were observed in the ceftriaxone treatment group.
Conclusion: We could conclude that once a day intravenous cefodizime therapy was as effective and well tolerated as ceftriaxone in the treatment of community-acquired pneumonia.
|
|
|
Keywords : Cefodizime, Community-Acquired Pneumonia, Efficacy. |
|
|
|
|
|
|
|
|
